Top Telehealth Companies With Best Stability & Growth (614)

Profitability: FY26 adjusted EBITDA rose 14% to $357.8 million with a mid‑50s margin, indicating strong earnings power even as investments increase. Management also highlighted sustained profitability alongside product expansion.

Healthy Cash Flow: Free cash flow grew 19% year over year to $317.5 million in FY26, with Q4 FY26 free cash flow of $107.3 million up double digits. These trends suggest solid cash generation supporting reinvestment and capital flexibility.

Strong Market Position & Advantage: The platform reports over 3 million members and reach to more than 85% of U.S. physicians, with record engagement of 800,000+ active prescribers on workflow tools. This scale can attract healthcare and life‑science spend and underpins monetization.

Strong Revenue Growth: Hiring materials and company statements describe “explosive growth” and cite “500% year‑over‑year growth” since 2022, indicating rapid top‑line momentum. Industry coverage continues to list the company among active GLP‑1 telehealth brands in a fast‑growing category.

Market Expansion: Announcements in 2025 detail enhanced national platform capabilities and the launch of in‑network plans, alongside licensure claims across all 50 states and a sizable increase in the provider network. Ongoing job postings and visible senior roles support an expanding operational footprint.

Product Line Growth: Company communications note a move beyond weight loss into broader metabolic health and additional categories such as mental health, hormones, hair loss, and dermatology. New insurance‑based offerings are framed as part of scaling access.

Profitability: Disclosures indicate the company is profitable and cash‑flow positive, with commentary pointing to disciplined, efficient operations.

Strong Revenue Growth: Company communications describe accelerating growth and multi‑year revenue expansion alongside meeting efficiency benchmarks.

Strategic Partnerships: Announcements highlight a first payer integration and expanded distribution through major channels like provider websites and large consumer platforms, broadening reach and access.

Strong Revenue Growth: External estimates indicate rapid revenue expansion in 2024, with growth outpacing prior periods and signaling accelerating scale.

Market Expansion: Company disclosures describe nationwide therapy availability, an expanding psychiatry footprint, and over 10 million facilitated sessions, pointing to broader reach and utilization.

Strategic Partnerships: Materials highlight a wide in‑network footprint and added payer/referral partnerships (e.g., OptumCare and Sidecar Health), supporting continued access and distribution.

Market Expansion: Covered lives reportedly grew from more than 15 million in 2021 to more than 26 million by 2025, spanning all 50 U.S. states and Latin America. New collaborations and a 2026 national employer-focused engagement signal continued reach into additional markets.

Product Line Growth: The company rebranded in 2024 and launched multiple offerings including agent-to-agent functionality, an end-to-end Navigator platform, and AI agents for wellness and behavioral health. This broadened portfolio positions the platform to address more member use cases across navigation and care.

Strategic Partnerships: Collaborations with organizations such as League, Google Cloud, FCamara, Protera Health, and a national employer-focused care management group indicate expanding partner channels. These relationships suggest access to new segments and support for international and enterprise growth.

Investor Backing & Capital Strength: Feedback suggests capital strength with a $72M Series C in May 2025 bringing total funding to $162M, led by Adams Street Partners with participation from major insurers. These resources are positioned to accelerate innovation, product development, and market reach.

Strong Revenue Growth: Feedback suggests revenue has expanded sharply, with claims of 300%+ growth since the prior round and a tenfold increase over two years. Third‑party trackers also cite rising ARR into 2025, though with caveats on methodology.

Strategic Partnerships: Feedback suggests deep partnerships across insurers and employers, including eight of the top ten U.S. life carriers and recent collaborations with Aflac, New York Life, and Voya. The company also formed the Empathy Alliance and broadened access in Canada through iA Financial Group and others.

Investor Backing & Capital Strength: Recent $15.5M Series A led by recognized investors is cited as fuel to scale access, expand operations, and invest in product. Feedback suggests this financing underpins continued hiring and multi-state rollout.

Market Expansion: Expansion beyond New York into states like Ohio and New Jersey and growing school-district partnerships indicate a widening footprint. Feedback suggests ongoing district announcements and state coverage are expected to continue post-Series A.

Strategic Partnerships: Direct partnerships with school districts and a model that accepts most commercial and Medicaid plans position the company to accelerate uptake in K‑12. Feedback suggests payer integrations and school workflows are central to its go-to-market.

Market Expansion: Public LinkedIn metrics (follower growth and an upgraded size band), multi‑state coverage claims, and frequent programming updates indicate a widening footprint. Feedback suggests the company’s audience and service reach have expanded from 2025 to 2026.

Strong Hiring & Retention: Active postings for senior roles via Built In and Paraform and recent role announcements on LinkedIn point to continued team build‑out. Feedback suggests the organization is staffing across engineering, operations, and new vertical leadership.

Strategic Partnerships: Mentions of Medicare in‑network access and co‑hosted senior‑care programming indicate developing channel relationships. These collaborations are typical of scaling distribution and referral networks.

Investor Backing & Capital Strength: A recent $100M Series C following prior rounds brings total funding to about $215M, indicating strong capacity to scale. A 2025 valuation milestone around $1B reinforces sustained investor confidence.

Strong Revenue Growth: Revenue reportedly reached $111.9M in 2024 with consistent year-over-year increases since launch. Company communications describe continued momentum into 2025–2026.

Market Expansion: The clinical network expanded rapidly to thousands of W‑2 dietitians across all 50 states and a broader pool cited at 10,000+ RDs, enabling nationwide access. Partnerships with hundreds of health plans covering over 200 million Americans and completion of millions of appointments signal widening reach.

Investor Backing & Capital Strength: A large Series D round in February 2026 led by a top-tier investor at a unicorn valuation signals strong capital support. The new funding is described as runway for headcount, product development, and market expansion.

Strong Revenue Growth: Company communications around the 2026 financing cite rapid year-over-year revenue gains. This momentum is positioned as evidence of increasing commercial adoption.

Market Expansion: Public materials reference a growing base of hundreds of organizations and new health-system partnerships announced in 2026. Ongoing hiring and new launches in May 2026 indicate active go-to-market execution.

Investor Backing & Capital Strength: Recent funding announcements, including a $50M Series B in April 2025 following a 2024 Series A, signal strong investor confidence and added runway. The round was described as oversubscribed with continued participation from existing investors.

Strategic Partnerships: New integrations and partnerships in 2026 (Workday Wellness Program and PrismHR) broaden distribution channels and ecosystem reach. Additional collaborations across 2025–2026 indicate deepening access to employers via HR/PEO channels.

Product Line Growth: Early 2026 launches such as AI-powered Claims Analytics and a cash‑pay network reflect active product investment and a widening solution set. These rollouts suggest accelerating roadmap execution to address employer cost containment and analytics needs.

Market Expansion: Public announcements indicate Sprinter expanded Care+ preventive home visits from 18 states in mid‑2025 to roughly half the nation (~25 states) by February 19, 2026. Additional references through 2025 outline continued launches, suggesting sustained geographic scaling.

Investor Backing & Capital Strength: Funding disclosures show a $55M Series B in May 2025, bringing reported total capital to about $125M. Coverage describes proceeds earmarked for multi‑state growth and technology/logistics, signaling capacity to finance expansion.

Strategic Partnerships: Documented programs with payers (e.g., Central California Alliance for Health and plan notices in New Hampshire) indicate expanding health plan relationships. Company and press materials also cite collaborations with health systems to close care gaps.

Innovation-Driven Growth: Recent 2026 launches such as RethinkBH’s AI Dashboard and Session Note AI, alongside major RethinkCare enhancements, signal active investment in new capabilities. These moves emphasize AI-enabled features to expand value for ABA practices and employers.

Future-Ready Strategy: Leadership additions—including a new CEO in 2026 and multiple senior hires in 2025—are framed as steps to accelerate innovation and scale. This pattern aligns with a company preparing for its next phase of growth.

Strong Revenue Growth: Repeated inclusion on the Inc. 5000 through 2024 indicates sustained multi‑year revenue expansion leading up to those recognitions. While historical, these accolades corroborate a prior growth trajectory.

Strong Revenue Growth: Independent analyses and transaction data indicate renewed topline momentum in 2024, largely powered by the scale‑up of Ro Body after its 2023 launch. Company and third‑party signals point to continued growth into 2025–2026.

Strategic Partnerships: Ro announced an integration with Novo Nordisk’s NovoCare Pharmacy to provide members access to FDA‑approved Wegovy at a defined cash price, aligning pricing and distribution with scaling demand. Additional manufacturer‑aligned moves and ongoing clinical activity reinforce access and credibility.

Diversified Revenue Streams: Analysts note that while GLP‑1 programs drove incremental gains by late 2024, Ro’s vertically integrated platform still supports non‑obesity lines such as ED, dermatology, and fertility. Outcomes publications and tooling (e.g., supply tracker) can support cross‑line adoption and stability.